Doximity (DOCS) closed at $65.61, down 9.59% from the previous session, underperforming the S&P 500, Dow, and Nasdaq. The stock rose by 3.29% in the past month, beating the Medical sector’s gain but falling short of the S&P 500. Analysts expect Doximity to report earnings of $0.38 per share and revenue of $157.73 million, showing growth from last year.

The Zacks Consensus Estimates predict full-year earnings of $1.51 per share and revenue of $632.56 million for Doximity. Positive estimate revisions indicate optimism about the business outlook and may impact stock performance. Doximity currently has a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 48.18, higher than industry average.

Zacks’ Research Chief recommends a stock with potential to double in value. Director of Research Sheraz Mian believes one pick stands out among the Top 5 recommendations. Previous recommendations like Hims & Hers Health saw a significant increase. Stay updated on stock-moving metrics through Zacks.com for upcoming trading sessions.

Read more at Nasdaq: Here’s Why Doximity (DOCS) Fell More Than Broader Market